中国临床药理学杂志2016，Vol.32Issue(14)：1261-1264,4.DOI:10.13699/j.cnki.1001-6821.2016.14.004
依达拉奉联合脑苷肌肽治疗重症颅脑损伤的临床研究
Clinical trial of edaravone combined with cattle encephalon glycoside and ignotin in the treatment of severe traumatic brain injury
摘要
Abstract
Objective To evaluate the efficacy and safety of edaravone combined with cattle encephalon glycoside and ignotin in the treatment of severe traumatic brain injury .Methods A total of 74 cases with severe traumatic brain injury were divided into control group ( n =37 ) and treatment group ( n =37 ) .Control group was given cattle encephalon glycoside and ignotin injection 10 mL, intravenous infusion, qd.Treat-ment group was received edaravone 30 mg, intravenous infusion , qd, on the basis of control group .Two groups were treated for two cycles with 28 d per cycle.The clinical efficacy , brain ede-ma area, the scores of acute physiology and chronic health evaluation Ⅱ(APACHE-Ⅱ), glasgow coma scale(GCS) and activities of daily living scale (ADL), levels of glial fibrillary acidic protein (GFAP), S100 calcium -binding protein( S100β) , heme oxygenase 1 ( HO -1 ) , matrix metalloproteinase -9 ( MMP -9 ) , hematocrit ( HCT ) and erythrocyte sedimentation rate ( ESR ) and incidence of adverse drug reactions were compared in two groups . Results After treatment, the total effective rate in treatment group was 94.59%(35/37), which was significantly higher than that in control group [ 81.08%( 30/37 ) , P<0.05 ] .There was no significant difference of the HCT in control group after and before treatment [(44.30 ±5.19)%vs (46.03 ±5.50)%, P>0.05], and the level of HCT in treatment group after treatment was significantly lower than that before treatment [ ( 40.15 ±4.44 )% vs (46.15 ±5.47)%, P<0.05].After treatment, the main observation indexes in treatment and control group: brain edema area were ( 12.46 ±1.42 ) , ( 18.46 ±1.96 ) cm2; APACHE -Ⅱ score were ( 10.19 ±1.13 ) , ( 13.57 ± 1.52 ) point;serum GFAP were ( 6.54 ±0.67 ) , ( 13.77 ±1.42 ) ng・ L-1; serum S100 βwere ( 0.07 ±0.01 ) , (0.09 ±0.01) μg・ L-1; serum HO -1 were (4.73 ±0.49), (11.74 ±1.25)μg・ L-1; serum MMP -9 were (137.67 ±15.53), (167.65 ±17.53)g・ mL-1 and ESR were (3.01 ±0.33), (3.88 ±0.48)mm・ h -1, also those indexes in treatment group after treatment were significantly lower than those in control group (P<0.05).After treat-ment , among the treatment and control group , the scores of GCS were ( 15.33 ±1.62 ) , ( 9.63 ±0.98 ) point and scores of ADL were (57.24 ±6.01), (46.35 ±4.72) point, and those indexes in treatment group after treatment were significantly higher than those in control group ( P<0.05 ) .The adverse drug reactions were based on abnormal liver function, nausea, vomiting and rash for two groups.Also, the incidences of adverse drug reactions in treatment and control group were 8.11%, 18.92%, respectively , without significant difference ( P > 0.05 ) . Conclusion Edaravone combined with cattle encephalon glycoside and ignotin have a definitive clinical efficacy and safety for the treatment of severe traumatic brain injury .关键词
依达拉奉/脑苷肌肽/重症颅脑损伤/安全性Key words
edaravone/cattle encephalon glycoside and ignotin/severe traumatic brain injury/safety分类
医药卫生引用本文复制引用
陈奇翰,林丹,邓钢,周键,龚江标..依达拉奉联合脑苷肌肽治疗重症颅脑损伤的临床研究[J].中国临床药理学杂志,2016,32(14):1261-1264,4.基金项目
浙江省医药卫生一般研究计划基金资助项目 （）
